UBE2H: A Potential Drug Target for Neurological Disorders (G7328)

Target Name: UBE2H

NCBI ID: G7328

UBE2H

UBE2H: A Potential Drug Target for Neurological Disorders

UBE2H (UBE2H variant 1) is a protein that is expressed in the endoplasmic reticulum (ER) and is involved in the regulation of the blood-brain barrier (BBB). The BBB is a specialized barrier that separates the brain from the blood and plays a crucial role in ensuring that only essential nutrients and medications can enter the brain. UBE2H is a key regulator of the BBB and has been identified as a potential drug target or biomarker for various neurological and psychiatric disorders.

UBE2H is a 21-kDa protein that is expressed in the ER and is composed of two transmembrane domains and an intracellular loop. The transmembrane domains are involved in the regulation of the BBB and the intracellular loop is involved in the regulation of the activity of the BBB. UBE2H is highly conserved, with sequence homology across various species, including humans.

The BBB is a specialized barrier that separates the brain from the blood and plays a crucial role in ensuring that only essential nutrients and medications can enter the brain. The BBB is composed of various proteins, including endothelial cell-derived growth factors (EGFR), occludin, and tight junction proteins. UBE2H is one of the tight junction proteins that are involved in the regulation of the BBB.

UBE2H is involved in the regulation of the BBB by promoting the formation of tight junctions between endothelial cells and by inhibiting the activity of EGFR, a transcription factor that is involved in the regulation of cell growth and survival. UBE2H promotes the formation of tight junctions by interacting with the cytoplasmic tail of EGFR and with the transmembrane domain of UBE2H.

UBE2H is also involved in the regulation of the BBB by interacting with the transmembrane domain of tight junction protein, ZO-1. UBE2H binds to ZO-1 and enhances its stability, which can lead to an increase in the activity of ZO-1 and the formation of tight junctions.

In addition to its role in the regulation of the BBB, UBE2H is also involved in the regulation of various cellular processes, including cell adhesion, migration, and the regulation of ion channels. UBE2H is also involved in the regulation of the cytoskeleton and is involved in the organization of the endoplasmic reticulum.

UBE2H has been identified as a potential drug target or biomarker for various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia. Alterations in UBE2H expression have been observed in the brains of individuals with these disorders, which may suggest that UBE2H plays a role in the pathogenesis of these disorders.

In conclusion, UBE2H is a key regulator of the BBB and is involved in the regulation of various cellular processes, including cell adhesion, migration, and the regulation of ion channels. UBE2H has been identified as a potential drug target or biomarker for various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia. Further research is needed to understand the role of UBE2H in the pathogenesis of these disorders and to develop effective treatments.

Protein Name: Ubiquitin Conjugating Enzyme E2 H

Functions: Accepts ubiquitin from the E1 complex and catalyzes its covalent attachment to other proteins (PubMed:8132613, PubMed:17588522, PubMed:20061386). E2 ubiquitin conjugating enzyme that transfers ubiquitin to MAEA, a core component of the CTLH E3 ubiquitin-protein ligase complex (PubMed:29911972). In vitro catalyzes 'Lys-11'- and 'Lys-48'-linked polyubiquitination (PubMed:20061386). Capable, in vitro, to ubiquitinate histone H2A (PubMed:8132613)

The "UBE2H Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UBE2H comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets